Introduction to CCDC180, A Potential Drug Target (G100499483)

Target Name: CCDC180

NCBI ID: G100499483

CCDC180

Introduction to CCDC180, A Potential Drug Target

CCDC180, also known as coiled-coil domain-containing protein 180, has emerged as an intriguing drug target and potential biomarker in various diseases. This article aims to shed light on the importance of CCDC180 and its potential implications in healthcare.

Understanding CCDC180

CCDC180 is a protein that belongs to the coiled-coil domain-containing (CCDC) family. It is primarily found in the cytoplasm and acts as a scaffold protein, facilitating interactions between other proteins in the cell. CCDC180 has been reported to play a crucial role in diverse cellular processes, including cell division, DNA repair, and intracellular transport.

CCDC180 in Cancer

The dysregulation of CCDC180 has been implicated in various types of cancer, making it an important target for drug development and potential biomarker identification. Several studies have shown that abnormal expression of CCDC180 is associated with tumor progression and metastasis, indicating its involvement in cancer development.

One particular study conducted on patients with colorectal cancer found that CCDC180 expression was significantly higher in tumor tissues compared to adjacent normal tissues. High CCDC180 expression was also correlated with advanced tumor stages and poor prognosis, suggesting its potential as a prognostic biomarker in colorectal cancer.

Similar observations have been made in breast cancer research, where higher CCDC180 expression was found in tumor tissues compared to healthy breast tissues. This aberrant expression was associated with poor survival outcomes and increased tumor aggressiveness, emphasizing the significance of CCDC180 as a potential therapeutic target in breast cancer.

Targeting CCDC180 for Therapeutic Intervention

The crucial role of CCDC180 in cancer progression has unveiled an opportunity for therapeutic intervention. By targeting CCDC180, researchers aim to disrupt its interactions with other proteins, inhibiting the cellular processes essential for tumor growth and metastasis.

One approach being explored is the development of small molecule inhibitors that specifically target CCDC180. These inhibitors can potentially bind to CCDC180 and block its interaction with partner proteins, hindering the progression of cancer cells.

Another strategy under investigation involves the use of RNA interference (RNAi) to selectively silence CCDC180 expression. By utilizing specific siRNA molecules, researchers can deliver RNAi agents to cancer cells, leading to the degradation of CCDC180 mRNA. This approach has shown promising results in preclinical studies, reducing tumor growth and metastasis in animal models.

Potential Use as a Biomarker

In addition to its role as a drug target, CCDC180 also holds promise as a biomarker in disease diagnosis and prognosis. The aberrant expression of CCDC180 in various cancers suggests its potential as a diagnostic indicator.

Real-time quantitative polymerase chain reaction (qPCR) has been used in several studies to detect CCDC180 mRNA expression levels in patient samples. This non-invasive method allows for the assessment of CCDC180 expression, aiding in the early detection and monitoring of cancer progression.

Furthermore, CCDC180 expression levels have been associated with treatment response in some cancers. For instance, in non-small cell lung cancer, patients with high CCDC180 expression showed a better response to certain chemotherapy regimens compared to those with low expression levels. This highlights the potential of CCDC180 as a predictive biomarker, aiding in treatment selection and individualized patient care.

Conclusion

CCDC180 has emerged as an essential protein in cancer biology, with implications as both a drug target and potential biomarker. Its dysregulation in various cancers underscores its involvement in tumor progression and metastasis. Targeting CCDC180 through small molecule inhibitors or RNA interference holds promise for therapeutic intervention. Additionally, CCDC180's expression levels can serve as a valuable biomarker in disease diagnosis and prognosis, aiding in early detection and treatment response prediction. Further research and clinical validation are needed to fully exploit the potential of CCDC180 in improving patient outcomes and shaping personalized healthcare.

Protein Name: Coiled-coil Domain Containing 180

The "CCDC180 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC180 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets